SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 4, 2013, Pages 301-307

  Wang, L ^a,b   Zhang, J ^a,c   Yang, X ^a   Chang, Y W Y ^d   Qi, M ^a   Zhou, Z ^a   Han, B ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Epithelial mesenchymal transition; Metastasis; Prognosis; SOX4

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SOX4; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; BIOACCUMULATION; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CELL CYCLE S PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LABELING INDEX; MALE; MOLECULAR DYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHINA; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOXC TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887615592     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.25     Document Type: Article

References (28)

1. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24: 1967-2000.
2. Castelli T, Cimino S, Magno C, Morgia G. Molecular markers for prostatic cancer. Front Biosci (Elite Ed) 2010; 2: 641-656.
3. Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002; 3: 167-170.
4. Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J et al. Microarraybased classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21: 1198-1203.
5. Lin B, Madan A, Yoon JG, Fang X, Yan X, Kim TK et al. Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. PLoS One 2010; 5: e10210.
6. Liao YL, Sun YM, Chau GY, Chau YP, Lai TC, Wang JL et al. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene 2008; 27: 5578-5589.
7. Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S et al. The SRYHMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet 2009; 18: 1343-1352.
8. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006; 66: 3434-3442.
9. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB et al. Sexdetermining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66: 4011-4019.
10. Suzuki T, Shen H, Akagi K, Morse HC, Malley JD, Naiman DQ et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002; 32: 166-174.
11. Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS. Genomewide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 2009; 69: 709-717.
12. Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol 2011; 8: 428-439.
13. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005; 65: 5991-5995.
14. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010; 5: e12445.
15. Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X et al. SOX4 induces epithelialmesenchymal transition and contributes to breast cancer progression. Cancer Res 2012; 72: 4597-4608.
16. Korshunov A, Sycheva R, Gorelyshev S, Golanov A. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 2005; 18: 1258-1263.
17. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22: 1083-1093.
18. Jafarnejad SM, Wani AA, Martinka M, Li G. Prognostic significance of Sox4 expression in human cutaneous melanoma and its role in cell migration and invasion. Am J Pathol 2010; 177: 2741-2752.
19. Wang L, Zheng Y, Xu H, Yan X, Chang X. Investigate pathogenic mechanism of TXNDC5 in reumatoid arthritis. PLoS One 2013; 8: e53301.
20. Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y et al. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Int J Oncol 2006; 28: 807-814.
21. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro J et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008; 68: 7629-7637.
22. Han B, Zhou G, Zhang Q, Zhang J, Wang X, Tang W et al. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J Exp Ther Oncol 2004; 4: 335-342.
23. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 437-441.
24. Moreno CS. The sex-determining region Y-box and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. Am J Pathol 2010; 176: 518-527.
25. Andersen CL, Christensen LL, Thorsen K, Schepeler T, Sorensen FB, Verspaget HW et al. Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer 2009; 100: 511-523.
26. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-152.
27. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: S3-S8.
28. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM.. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgenindependence. Br J Cancer 2004; 90: 449-454.